Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, has completed the previously announced sale of its mass spectrometry business to Danaher Corporation (NYSE: DHR) for $450 million in cash, subject to a conventional working capital adjustment.
Danaher has also acquired Life Technologies’ joint venture partner in the business, MDS Analytical Technologies, a division of MDS Inc. (NYSE: MDZ). Mass spectrometers are highly sensitive and sophisticated instruments used by researchers and clinicians to identify and quantify specific molecules in complex samples.
As previously announced, Life Technologies does not expect the sale of its mass spectrometry business to affect its previously announced 2009 and 2010 earnings expectations.
Source: Life Technologies Corporation
UIC to determine whether exercise can shorten recovery time for stem cell transplant patients